Wednesday, April 17, 2024

DMTK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

DMTK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case


SAN DIEGO, Nov. 05, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DermTech, Inc. (NASDAQ:DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the "Class Period"), have until December 15, 2023 to seek appointment as lead plaintiff of the DermTech class action lawsuit. Captioned Bagheri v. DermTech, Inc., No. 23-cv-01885 (S.D. Cal.), the DermTech class action lawsuit charges DermTech as well as certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the DermTech class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-dermtech-inc-class-action-lawsuit-dmtk.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.

CASE ALLEGATIONS: DermTech is a molecular diagnostic company that develops and markets non-invasive genomics test to aid the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The DermTech Melanoma Test ("DMT") is a commercial test offered to assess pigmented skin lesions for melanoma.

The DermTech class action lawsuit alleges that defendants throughout the Class Period failed to disclose that: (i) DermTech experienced challenges with ...

Full story available on Benzinga.com